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Abstract. Background/Aim: Cortactin (CTTN) has been
considered a promising molecular prognostic factor in
various types of cancers. In this study, we aimed to
investigate the role of CTTN in the pathogenesis of cutaneous
squamous cell carcinoma (CSCC). Materials and Methods:
CTTN and phospho-CTTN (p-CTTN) expression was
determined in 10 healthy controls and 38 CSCC tissue
samples by immunohistochemistry. The influence of CTTN on
the biological behavior of CSCC cells was also investigated.
Results: p-CTTN expression was significantly increased in
CSCC than control samples. In contrast, no significant
difference in CTTN expression was found between control and
CSCC tissues. Moreover, a significant association was found
between recurrence-free survival with p-CTTN expression, but
not with CTTN expression. Furthermore, the proliferative,
migratory, and invasive abilities of CSCC cells were
significantly decreased by CTTN-siRNA transfection.
Conclusion: CTTN phosphorylation is strongly associated
with CSCC pathogenesis and may serve as a molecular
biomarker of CSCC. 
Cutaneous squamous cell carcinoma (CSCC) is the second
most common keratinocyte carcinoma (1). Although CSCC
has a relatively low recurrence and metastasis rate (2), its
incidence is rapidly increasing (3). As the molecular
pathogenesis of CSCC is heavily influenced by UV
radiation-induced mutagenesis, investigation into the
molecular basis of CSCC can provide more reliable
diagnostic biomarkers, as well as therapeutic targets.  
The Src family tyrosine kinases are known to be involved
in integrin-mediated biological processes including cell
proliferation, actin organization, and cell migration (4-9).
Some investigators have demonstrated that Src is frequently
hyperactivated in various types of cancers, particularly in
metastatic lesions (6, 10, 11). The critical roles of Src family
kinases are thought to be largely dependent on their
substrates, and cortactin is known as a direct substrate of
cellular Src kinase (12). 
As an actin binding protein, cortactin (CTTN) is encoded
by the CTTN gene, located at chromosome 11q13 and
enriched in the lamellipodia and membrane ruffles of cells;
it regulates actin dynamics and is known to be associated
with cell motility in vitro (13, 14). Overexpression and
amplification of CTTN are frequently detected in various
types of cancers and are considered a promising indicator of
poor prognosis (15-26). More recently, many researchers
have analyzed post-translational modifications of CTTN (16,
17, 27). Moreover, studies have demonstrated that tyrosine
phosphorylation of CTTN is mediated by various tyrosine
kinases such as Src (28, 29). 
Src can phosphorylate CTTN at the sites of three tyrosine
residues Tyr421, Tyr466, and Tyr482 in vitro (30). Src-
mediated CTTN phosphorylation has been reported to be
involved in the integrin-induced cell spreading and adhesion
process (31). Compared to CTTN, which is colocalized in
lamellipodia with Src and actin, tyrosine phosphorylated
CTTN (p-CTTN) is located at focal adhesions, especially at
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the ends of F-actin stress fibers, all three tyrosine residues
Tyr421, Tyr466, and Tyr482 of CTTN are being
phosphorylated upon focal adhesion (32, 33). Phosphorylation
of Tyr421, Tyr466, and Tyr482 of CTTN has frequently been
observed in vitro in many types of cells including cancer
cells, and is a critical factor in cell migration (29, 30, 34, 35).
In gastric cancer cell lines, decreased cell motility induced by
CTTN knockdown was restored by wild-type CTTN
overexpression, but not by CTTN mutated in tyrosine residues
such as Tyr421, Tyr466, and Tyr482 (36). Similar results have
also been reported in breast cancer cell lines (37). Moreover,
after transfecting mutant CTTN (Tyr 421/466/482),
endothelial cells presented decreased cell motility in vitro
(38). In spite of several in vitro studies demonstrating the
critical role of p-CTTN in the motility of several cell types,
little is known regarding the clinicopathological implications
of p-CTTN in cancer patients.  
In this study, we investigated the influence of CTTN
expression on the biological behavior of CSCC cell lines, for
the first time, as well as the clinicopathological significance
of both CTTN and p-CTTN in a cohort of CSCC patients. 
Materials and Methods
Clinical materials. In total, 10 normal skin and 38 CSCC tissue
specimens were included in this study. All specimens were obtained
from the Department of Pathology, Yonsei University Health System
in Seoul, Korea. The clinicopathological characteristics of the
patients are summarized in Table I. This study was approved by the
Institutional Review Board for Bioethics of Yonsei University
Health System, Severance Hospital (IRB 2018-0874-001). 
Immunochemical staining. For immunohistochemistry, the tissue
sections were deparaffinized with xylene and hydrated using a
graded ethanol. After antigen retrieval and blocking of endogenous
peroxidase activity, the sections were incubated with primary
antibody at RT for 1 h. Each group of cells was seeded in a chamber
slide (Thermo Fisher Scientific, Waltham, MA, USA) at a density
of 2×104. After 24 h of culture, the cells were fixed with 95%
ethanol for 30 min at RT, and then incubated with primary antibody
at RT for 1 h. Cortactin (Abcam, Cambridge, MA, USA), pTyr421-
CTTN (LifeSpan BioSciences, Seattle, WA, USA) and p Try466-
CTTN (LifeSpan BioSciences) were used in this study, and REAL
EnVision HRP Rabbit/Mouse Detection System (Dako, Santa Clara,
CA, USA) was used as secondary antibody. Visualization was
performed using the chromogen 3,3’-diaminobenzidine and
counterstaining was performed with hematoxylin. Rabbit IgG
(DakoCytomation Denmark A/S, Glostrup, Denmark) was used as
a negative control.
As described in a previous study, the weighted histoscore method
was used to score each protein expression according to staining
intensity and the percentage of positive cells (39). The tumour cell
intensity was scored as 0 (negative), 1 (light brown), 2 (brown), and
3 (dark brown). The histoscore was calculated as follows: Total
score=(0× percentage of negative cells) + (1× percentage of light-
brown cells) + (2× percentage of brown cells) + (3 × percentage of
dark-brown cells). Based on the total histoscore, the samples were
further divided into two expression groups, low (histoscores 0
through 100) and high (histoscores 101 through 300).
Cell lines and culture. Human CSCC cells (HSC-1 and HSC-5) were
obtained from the Japanese Collection of Research Bioresources
(Osaka, Japan) for use in this study. These cell lines were cultured
in Roswell Park Memorial Institute 1640 medium (Nissui
Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10%
foetal bovine serum (Invitrogen, Carlsbad, CA, USA), 100 U/ml
penicillin, and 0.1 mg/ml streptomycin-amphotericin B (Lonza,
Basel, Switzerland), at 37˚C under a humidified 5% CO2 atmosphere.
CTTN knockdown in these cells was performed by short-interfering
RNA (siRNA) transfection (siCTTN; invitrogen) using Lipofectamin
2000 (Invitrogen) according to the manufacturer’s protocol. A
scrambled (Scr)-siRNA (Bioneer, Korea) was used as negative
control. Knockdown efficiency was determined by reverse-
transcription real-time quantitative polymerase chain reaction (RT-
qPCR) and immunochemical staining. 
RT-qPCR. Total RNA was isolated from HSC-1 and HSC-5 cells after
transfection with CTTN-siRNA or Scr-siRNA using TRIzol Reagent
(Invitrogen) according to the manufacturer’s protocol. CTTN, marker
of proliferation Ki-67 (MKI67), and proliferating cell nuclear antigen
(PCNA) mRNA expression was investigated following
complementary DNA synthesis by qPCR analysis using 2× SYBR
Premix Ex Taq II (Tli RnaseH Plus) (RR82LR; Takara, Ann Arbor,
MI, USA) on an Applied Biosystems (Foster City, CA, USA)
instrument. The following primers were used: MKI67 forward: 5’-
CCCCCACCAGAACTAACAGA-3’ and reverse: 5’-ACTTTGAT
GCCCTCATCACC-3’; PCNA forward: 5’-GAAGCACCAAACCA
GGAGAA-3’ and reverse: 5’-TCACTCCGTCTTTTGCACAG-3’; β-
actin forward: 5’-ATAGCACAGCCTGGATAGCAACGTAC-3’ and
reverse: 5’-CACCTTCTACAATGAGCTGCGTGTG-3’. The relative
expression of each gene was normalized with β-actin mRNA
expression.
The influences of CTTN knockdown on the biological behaviour of
the CSCC cells. To investigate the influence of CTTN expression
on the biological behaviour of the cells, trypan blue assay, migration
assay, and matrigel invasion assay were performed in HSC-1 and
HSC-5 cells after transfection with CTTN-siRNA or Scr-siRNA. For
trypan blue assay, those cells were seeded in a 6-well plate at a
density of 1×104 and counted each day for 3 days after trypan blue
staining. For wound-healing assay, each group of cells were seeded
in a 24-well plate at a density of 3×104. At 90% confluency a
scratch wound was made, whose relative closure was investigated
after 24 h. For matrigel invasion assay, each group of cells was
seeded in a Matrigel-(BD Biosciences, San Jose, CA, USA) coated
upper chamber of a transwell (BD Biosciences, Bedford, MA, USA)
at a density of 5×104 with culture medium containing 1% FBS.
Culture medium containing 10% FBS was added in the bottom
chamber. After 30 h of culture, invading cells were stained with
0.25% crystal violet and counted under the microscope. 
Statistical analysis. The association between CTTN protein
expression and clinicopathological variables of CSCC patients was
analyzed with Fisher’s exact test. Mann–Whitney U-test was used
to examine the influences of CTTN knockdown on the biological
behavior of the CSCC cells. Differences were considered to be
statistically significant when p<0.05.
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Results
CTTN, pTyr421-CTTN, and pTry466-CTTN expression in
normal skin and CSCC tissue samples. Representative
expression patterns of CTTN, pTyr421-CTTN, and pTry466-
CTTN in the tissue samples are shown in Figure 1.
Cytoplasmic expression of CTTN, pTyr421-CTTN, and
pTry466-CTTN was frequently found in normal epithelial cells
and cancer cells in tissue specimens. No significant difference
was found between normal skin and CSCC samples in CTTN
protein expression. High-CTTN expression was found in 7
(70%) and 26 (68.4%) of the normal skin and CSCC tissue
samples, respectively (Figure 2A). In contrast, the frequency
of both high-pTyr421-CTTN and high-pTry466-CTTN
expression was significantly increased in CSCC tissues relative
to normal skin tissue samples (p=0.003, and p=0.008,
respectively). High-pTyr421-CTTN and high-pTry466-CTTN
expression was found in 21 (47.4%) and 18 (55.3%) CSCC
tissue samples, respectively. However, no normal skin tissue
samples exhibited high immunoreactivity for either pTyr421-
CTTN or high-pTyr466-CTTN (Figure 2A). 
The clinicopathological significance of the expression of
all three proteins in the 38 patients with CSCC was further
investigated. None of the baseline clinicopathological
parameters, including age, gender, site, tumor size, and
differentiation of involvement, were significantly associated
with tissue CTTN, pTyr421-CTTN, or pTyr466-CTTN
expression in patients with CSCC (Table II). Meanwhile,
Kaplan–Meier analysis showed that both pTyr421-CTTN and
pTry466-CTTN expression were significantly correlated with
recurrence-free survival of patients with CSCC. As a result,
patients with high expression of pTyr421-CTTN (median
survival duration of 29 months in the low expression group
versus 13.7 months in the high expression group; p=0.014)
or pTry466-CTTN (median survival duration of 47.4 months
in low expression group versus 12.0 months in high
expression group; p=0.006) exhibited poor recurrence-free
survival rates (Figure 2B). 
Efficient CTTN knockdown by siRNA transfection of human
CSCC cancer cell lines. CTTN knockdown in CSCC cell lines
was performed by siRNA transfection. Compared to Scr-siRNA
control, CTTN mRNA expression in HSC-1 cells transfected
with CTTN-siRNA was significantly decreased at 24 h
(0.24±0.04) (p<0.001), 36 h (0.22±0.05) (p<0.001), and 72 h
(0.44±0.01) (p<0.001) post siRNA transfection. CTTN-siRNA-
transfected HSC-5 cells also showed significantly reduced
CTTN mRNA expression at 24 h (0.30±0.04) (p<0.001), 36 h
(0.26±0.03) (p<0.001), and 72 h (0.41±0.02) (p<0.001) after
transfection, compared to the related Scr-siRNA group. CTTN,
pTyr421-CTTN, and pTry466-CTTN expression also
prominently decreased in the CTTN-siRNA group relative to the
Scr-siRNA group in both HSC-1 and HSC-5 cells (Figure 3A). 
CTTN knockdown attenuated CSCC cells proliferation.
Compared to Scr-siRNA control, the number of HSC-1 cells
transfected with CTTN-siRNA was significantly decreased
after siRNA transfection at 24h (0.64±0.08) (p<0.001), 36 h
(0.42±0.06) (p<0.001), and 72 h (0.44±0.03) (p<0.001). HSC-
5 cells yielded similar results: CTTN-siRNA-transfected HSC-
5 cells showed a significantly reduced number of the cells at
24 h (0.80±0.05) (p<0.001), 36 h (0.56±0.06) (p<0.001), and
72 h (0.31±0.03) (p<0.001) after transfection compared to the
related Scr-siRNA group. Moreover, compared to the Scr-
siRNA control, significantly decreased MKI67 (both p<0.001)
and PCNA (both p<0.001) mRNA expression were found in
both HSC-1 and HSC-5 cell lines at 24 h after CTTN siRNA
transfection (Figure 3B). 
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Table I. Clinicopathological variables of the tissue samples.
Clinicopathological variables
Normal skin tissues
   Total no. of cases                                                 10
Age
   Median age (range)                                            62 (42-87)
Gender, n (%)
   Male                                                                      5 (50)
   Female                                                                   5 (50)
Site, n (%)                                                                   
   Scalp                                                                      2 (20)
   Face                                                                       4 (40)
   Ear                                                                         2 (20)
   Acral                                                                      2 (20)
CSCC
   Total no. of cases                                                 38
Age
   Median age (range)                                            69 (42-89)
Gender, n (%)
   Male                                                                    19 (50)
   Female                                                                 19 (50)
Site, n (%)                                                                   
Scalp                                                                         6 (15.8)
   Face                                                                     17 (44.7)
   Ear                                                                         5 (13.2)
   Lip                                                                         4 (10.5)
   Acral                                                                      6 (15.8)
Size, cm
   Median size (range)                                               2.0 (0.5-4.5)
Differentiation
   Well                                                                     20 (52.6)
   Moderate                                                             14 (36.8)
   Poorly                                                                    4 (10.5)
Recurrence
   Yes                                                                       18 (47.4)
   No                                                                        20 (52.6)
Duration of follow-up
   Median (range, months)                                      21.7 (1.0-110.5)
Interval of recurrence
   Median (range, months)                                      11.0 (1.0-91.0)
CTTN knockdown attenuated CSCC cell migration and invasion.
The effect of CTTN on CSCC cell migration was investigated
using a wound-healing assay. Compared to the related Scr-
siRNA control, transfection of CTTN-siRNA significantly
reduced the migration ability of both HSC-1 and HSC-5 cells as
measured at 24 h after scratch wounding (Figure 3C). In
addition, the influence of CTTN on the invasion ability of CSCC
cells was investigated by a matrigel invasion assay. The number
of CTTN-siRNA transfected HSC-1 and HSC-5 cells having
traversed the membrane was found to be significantly decreased
(both p<0.001) compared to the Scr-control (Figure 3C). 
Discussion
Despite ongoing efforts to identify the role of CTTN in
tumorigenesis of various types of cancers, it has not been
investigated in CSCC. In this study, the influence of CTTN
knockdown on the proliferation, migration, and invasion
abilities of CSCC cell lines was investigated. Similar to other
cancers, CTTN knockdown significantly attenuated both the
migration and invasion ability of CSCC cells (21, 22).
Moreover, the proliferation ability of CSCC cell lines was
also decreased after CTTN knockdown. These data suggest
that cortactin may play a critical role in CSCC progression. 
Clinicopathological implications of CTTN overexpression
have been investigated in various types of cancers, such as
head and neck, colorectal, gastric cancers, renal cell carcinoma,
breast cancers, and osteosarcoma. Studies have demonstrated
that CTTN overexpression is significantly associated with
various indicators of poor prognosis including higher T stage,
lymph node metastasis, increased recurrence rates and
decreased overall survival in cancer patients (18-23, 40, 41).
in vivo 33: 393-400 (2019)
396
Figure 1. Representative expression patterns for CTTN, pTry421-, and pTry466-CTTN expression in normal skin (A, D, G) and CSCC tissue samples
(B, C, E, F, H, I). Cytoplasmic expression of CTTN was found in both normal skin and CSCC tissue samples. Original magnification: ×200; scale
bar=200 μm.  
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Figure 2. Clinicopathological associations of CTTN, pTry421-, and pTry466-CTTN expression in surgical samples. A: Significant difference was
found between normal skin and CSCC tissue samples in pTry421- and pTry466-CTTN expression, but not in CTTN expression (i-iii) (*p<0.05). B:
In CSCC patients, both pTry421-, and pTry466-CTTN expression showed a significant association with recurrence-free survival (ii and iii), but
CTTN expression did not (i) (*p<0.05).
Table II. Clinicopathological significance of CTTN, pTry421-CTTN, and pTry466-CTTN expression in 38 CSCC patients.
                                                                                             CTTN                                      pTry421-CTTN                            pTry466-CTTN
Variable                                    No. of cases, (%)      Low            High         p-Value        Low            High       p-Value       Low            High      p-Value
                                                                                                                                                                                                                                           
Age                      <69 years           19 (50)              3 (15.8)     16 (84.2)        0.079      12 (63.2)      7 (36.8)       0.33        8 (42.1)    11 (57.9)            1
                            ≥69 years           19 (50)              9 (47.4)     10 (52.6)                         8 (42.1)     11 (57.9)                      9 (47.4)    10 (52.6)              
Gender                 Male                   19 (50)              4 (21.1)     15 (78.9)        0.295      11 (57.9)      8 (42.1)     0.746        7 (36.8)    12 (63.2)     0.515
                            Female               19 (50)              8 (42.1)     11 (57.9)                         9 (47.4)    10 (52.6)                    10 (52.6)      9 (47.4)              
Site                       Scalp                    6 (15.8)          2 (33.3)       4 (66.7)           1            2 (33.3)      4 (66.7)     0.502        2 (33.3)      4 (66.7)     0.256
                            Face                    17 (44.7)          6 (35.3)     11 (64.7)                         8 (47.1)      9 (52.9)                    10 (58.8)      7 (41.2)              
                            Ear                        5 (13.2)          1 (20.0)       4 (80.0)                         3 (60.0)      2 (40.0)                      3 (60.0)      2 (40.0)              
                            Lip                        4 (10.5)          1 (25.0)       3 (75.0)                         2 (50.0)      2 (50.0)                      0 (0)           4 (100.0)            
                            Acral                    6 (15.8)          2 (33.3)       4 (66.7)                         5 (83.3)      1 (16.7)                      2 (33.3)      4 (66.7)              
Size                      <2.0 cm              17 (44.7)          4 (23.5)     13 (76.5)        0.486      10 (58.8)      7 (41.2)     0.532        9 (52.9)      8 (47.1)     0.513
                            ≥2.0 cm              21 (55.3)          8 (38.1)     13 (61.9)                       10 (47.6)     11 (52.4)                      8 (38.1)    13 (61.9)              
Differentiation     Well                    20 (52.6)          8 (40.0)     12 (60.0)        0.547      13 (65.0)      7 (35.0)     0.057      10 (50.0)    10 (50.0)     0.725
                            Moderate            14 (36.8)          3 (21.4)     11 (78.6)                         7 (50.0)      7 (50.0)                      6 (42.9)      8 (57.1)              
                            Poorly                  4 (10.5)          1 (25.0)       3 (75.0)                         0 (0)            4 (100)                       1 (25.0)      3 (75.0)              
In the present study, a strong CTTN expression was found in
CSCC tissue samples, but strong immunoreactivity to CTTN
was also frequently observed in normal skin tissue samples,
and the difference was not significant. Moreover, in our cohort
of CSCC, no significant association was found between CTTN
expression and clinicopathological parameters of patients.
Some previous studies have reported the absence of CTTN
expression in benign tissues, in contrast to the results of this
study (22, 25), while other studies have also found CTTN
expression in normal tissues (18-20). Furthermore, some
in vivo 33: 393-400 (2019)
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Figure 3. Knockdown of CTTN expression by CTTN-siRNA transfection in CSCC cell lines. A: Both protein (I and iii) and mRNA (ii and iv)
expression of CTTN were decreased by CTTN-siRNA transfection. B: Proliferation ability was significantly decreased in CTTN-siRNA transfected
HSC-1(i) and HSC-5(iii) cell lines compared to the scrambled control. Supportively, both Ki-67 (MKI-67) and proliferating cell nuclear antigen
(PCNA) mRNA expression were significantly decreased in CTTN-siRNA transfected HSC-1(ii) and HSC-5(iv) cell lines compared to the scrambled
control. C: Both cell motility (i and ii) and invasion ability (iii and iv) of the cell lines were significantly reduced after CTTN-siRNA transfection
relative to the scrambled control (*p<0.001).
investigators have shown increased CTTN expression in
benign tumor tissues compared to in malignant ones (42). The
CTTN expression levels in tissues may largely depend on the
tissue type in question. 
Recent findings indicate that Src-mediated p-CTTN
overexpression is more important for the migration ability of
cells than CTTN overexpression, there being no demonstrably
significant influence on migration ability of cells after
transfection of mutant type CTTN (Try421/466/482 mutation)
(36, 38). Moreover, decreased cell migration ability has been
observed after blocking tyrosine phosphorylation of CTTN (33).
Increased cell motility plays a critical role in various cell
pathological processes including metastasis and recurrence.
Some investigators have noticed overexpression of CTTN in
malignant tumors, and an association between CTTN
phosphorylation and increased cell motility, as well as metastasis
(6, 15). In this study, p-CTTN expression was detected using the
phospho-specific antibodies anti-pTyr421- and anti-pTyr466-
CTTN, and the results showed that the expression of both was
significantly increased in CSCC tissue samples relative to
normal skin tissues. Moreover, a significant association was
found between CTTN phosphorylation and recurrence-free
survival in CSCC patients. These findings indicate a crucial role
of p-CTTN expression in CSCC progression. 
The molecular mechanisms related to p-CTTN functions
remain largely unknown. As a F-actin related protein, CTTN
is known to cross-link F-actin into meshwork in vitro.
Tyrosine phosphorylation is known to inhibit the ability of
CTTN to cross-link F-actin, but it remains controversial
whether it affects the ability of CTTN to crosslink actin
filaments (43-45). Investigators have shown that CTTN
tyrosine phosphorylation controls cell functions by
establishing binding sites for effectors such as Nck and Src
family kinase (46). Further study is needed to clarify the
precise mechanism of p-CTTN function in CSCC. 
In summary, CTTN knockdown strongly influenced the
biological behavior of CSCC cell lines. Moreover, p-CTTN
expression was significantly increased in CSCC tissues
relative to normal skin samples, as well as being
significantly associated with recurrence-free survival of
CSCC patients. CTTN phosphorylation may thus be involved
in CSCC pathogenesis. These findings also provide evidence
that p-CTTN may serve as a predictive biomarker, as well as
therapeutic target in CSCC patients. A larger patient cohort
is needed to investigate the clinicopathological implications
of both cortactin and p-CTTN for CSCC pathogenesis.  
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